BiomX(PHGE) - 2023 Q1 - Quarterly Report

FORM 10-Q Filing Information This section provides details on BiomX Inc.'s Form 10-Q filing, including company classification, NYSE American listings, and outstanding common stock as of May 9, 2023 Filing Details BiomX Inc. filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, incorporated in Delaware with principal offices in Israel, and its securities are registered on the NYSE American - BiomX Inc. filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2023[1] - The company's securities (Units, Common Stock, Warrants) are traded on the NYSE American under symbols PHGE.U, PHGE, and PHGE.WS, respectively[4] - BiomX Inc. is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company[5] Outstanding Shares As of May 9, 2023, BiomX Inc. had 45,979,730 shares of common stock issued and outstanding - As of May 9, 2023, 45,979,730 shares of common stock, par value $0.0001 per share, were issued and outstanding[6] CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION This section details the nature of forward-looking statements and outlines key risks that could materially affect BiomX Inc.'s future results and financial condition Forward-Looking Statements and Risks This section outlines the forward-looking statements within the report and highlights significant risks and uncertainties that could cause actual results to differ materially. Key risks include the ability to generate revenue and secure financing, unpredictable timing and cost of phage technology development, political and economic instability (including in Israel), regulatory approvals, patient enrollment in clinical trials, competition, intellectual property protection, and the impact of COVID-19 - Forward-looking statements include discussions on operations, cash flows, financial position, business strategy, clinical and pre-clinical development programs, and sufficiency of financial resources[10] - Key risks include the ability to generate revenues and raise sufficient financing, unpredictable timing and cost of phage technology development, political and economic instability (including in Israel), obtaining FDA acceptance for non-U.S. clinical trials, and the ability to enroll patients in clinical trials[10] - Other risks involve competition, intellectual property rights, reliance on third-party collaborators, ability to attract and retain key employees, and potential security breaches[13] PART I - FINANCIAL INFORMATION This section presents BiomX Inc.'s unaudited condensed consolidated financial statements and management's discussion and analysis for the quarter ended March 31, 2023 Item 1. Financial Statements This section presents the unaudited condensed consolidated financial statements for BiomX Inc., including the balance sheets, statements of operations, statements of changes in stockholders' equity, and statements of cash flows, along with their accompanying notes. The financial data reflects the company's financial position and performance for the quarter ended March 31, 2023, compared to prior periods Condensed Consolidated Balance Sheets The balance sheets provide a snapshot of BiomX Inc.'s assets, liabilities, and equity as of March 31, 2023, and December 31, 2022 | Metric (USD in thousands) | March 31, 2023 | December 31, 2022 | Change | % Change | | :------------------------ | :------------- | :---------------- | :----- | :------- | | Cash and cash equivalents | 29,346 | 31,332 | (1,986) | -6.34% | | Total current assets | 32,934 | 36,881 | (3,947) | -10.70% | | Total assets | 41,407 | 45,531 | (4,124) | -9.06% | | Total current liabilities | 10,200 | 7,939 | 2,261 | 28.48% | | Total non-current liabilities | 15,061 | 16,553 | (1,492) | -9.01% | | Total stockholders' equity | 16,146 | 21,039 | (4,893) | -23.26% | Condensed Consolidated Statements of Operations The statements of operations detail BiomX Inc.'s revenues, expenses, and net loss for the three months ended March 31, 2023, and 2022 | Metric (USD in thousands) | Three Months Ended March 31, 2023 | Three Months Ended March 31, 2022 | Change | % Change | | :------------------------ | :-------------------------------- | :-------------------------------- | :----- | :------- | | R&D expenses, net | 4,564 | 4,929 | (365) | -7.40% | | Amortization of intangible assets | - | 380 | (380) | -100.00% | | General and administrative expenses | 1,644 | 2,477 | (833) | -33.63% | | Operating loss | 6,208 | 7,786 | (1,578) | -20.27% | | Interest expenses | 565 | 461 | 104 | 22.56% | | Finance income, net | (327) | (87) | (240) | 275.86% | | Net loss | 6,361 | 8,169 | (1,808) | -22.13% | | Basic and diluted loss per share | 0.20 | 0.27 | (0.07) | -25.93% | Condensed Consolidated Statements of Changes in Stockholders' Equity This statement outlines changes in BiomX Inc.'s stockholders' equity, including common stock, additional paid-in capital, and accumulated deficit, for the period | Metric (USD in thousands) | As of January 1, 2023 | As of March 31, 2023 | | :------------------------ | :-------------------- | :------------------- | | Common Stock Shares | 29,976,582 | 33,176,073 | | Additional Paid-in Capital | 157,838 | 159,306 | | Accumulated Deficit | (136,801) | (143,162) | | Total Stockholders' Equity | 21,039 | 16,146 | - Issuance of Common Stock and warrants under Private Investment in Public Equity (PIPE) contributed $1,293 thousand (net of issuance costs) to additional paid-in capital during Q1 2023[29] - Net loss of $6,361 thousand significantly reduced stockholders' equity during Q1 2023[29] Condensed Consolidated Statements of Cash Flows The cash flow statements categorize cash movements from operating, investing, and financing activities for the three months ended March 31, 2023, and 2022 | Metric (USD in thousands) | Three Months Ended March 31, 2023 | Three Months Ended March 31, 2022 | Change | % Change | | :------------------------ | :-------------------------------- | :-------------------------------- | :----- | :------- | | Net cash used in operating activities | (5,045) | (7,363) | 2,318 | -31.48% | | Net cash provided by (used in) investing activities | 1,990 | (10,020) | 12,010 | -120.06% | | Net cash provided by financing activities | 1,050 | 37 | 1,013 | 2737.84% | | Decrease in cash and cash equivalents and restricted cash | (2,005) | (17,346) | 15,341 | -88.44% | | Cash and cash equivalents and restricted cash at end of period | 30,302 | 45,745 | (15,443) | -33.76% | Notes to Condensed Consolidated Financial Statements These notes provide additional information and explanations for the figures presented in BiomX Inc.'s condensed consolidated financial statements NOTE 1 – GENERAL BiomX Inc. is a clinical-stage company developing phage cocktails for chronic diseases, primarily cystic fibrosis. The company has not generated revenue to date but believes its current cash is sufficient for over 12 months. It expects to incur further losses and plans to fund operations through future debt/equity issuances, loans, and grants. A corporate restructuring in May 2022 prioritized the cystic fibrosis program and delayed the atopic dermatitis program to extend capital resources - BiomX is developing natural and engineered phage cocktails to target harmful bacteria in chronic diseases, focusing on cystic fibrosis and, to a lesser degree, atopic dermatitis[44] - The company has not generated revenue from operations and expects current cash and cash equivalents to fund operations for more than 12 months from the issuance date of these financial statements[45] - A corporate restructuring in May 2022 prioritized the cystic fibrosis program and delayed the atopic dermatitis program to extend capital resources[46] NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES The unaudited condensed consolidated financial statements are prepared in accordance with U.S. GAAP, using management estimates and assumptions. The company adopted ASU 2016-13 on January 1, 2023, which did not have a material impact on its financial statements. The potential impact of the COVID-19 pandemic remains uncertain - The financial statements are prepared in accordance with U.S. GAAP for condensed financial information and rely on management's estimates and assumptions[49][52] - The company adopted ASU 2016-13 on January 1, 2023, and concluded it did not have a material impact on its consolidated financial statements[54] NOTE 3 – FAIR VALUE OF FINANCIAL INSTRUMENTS The company categorizes financial instruments using a three-level fair value hierarchy. As of March 31, 2023, cash equivalents (money market funds) were Level 1, foreign exchange contracts were Level 2, and contingent consideration was Level 3. The fair value of contingent consideration is based on a probability discounted cash flow analysis with significant unobservable inputs | Financial Instrument (USD in thousands) | March 31, 2023 Fair Value | December 31, 2022 Fair Value | | :------------------------------------ | :------------------------ | :--------------------------- | | Assets: | | | | Money market funds (Level 1) | 23,897 | 27,824 | | Liabilities: | | | | Contingent consideration (Level 3) | 152 | 148 | | Foreign exchange contracts payable (Level 2) | 95 | 55 | - The fair value of contingent consideration is determined using a probability discounted cash flow analysis, relying on significant unobservable inputs (Level 3)[59] - The company uses foreign exchange contracts (Level 2) to hedge currency exposure, with outstanding contracts of approximately $4,647 thousand (USD to NIS) as of March 31, 2023[60] NOTE 4 – OTHER CURRENT ASSETS Other current assets primarily consist of prepaid insurance and grants receivables. As of March 31, 2023, total other current assets were $2,632 thousand, a slight increase from $2,587 thousand at December 31, 2022 | Other Current Assets (USD in thousands) | March 31, 2023 | December 31, 2022 | | :------------------------------------ | :------------- | :---------------- | | Government institutions | 47 | 90 | | Prepaid insurance | 1,545 | 1,410 | | Other prepaid expenses | 171 | 84 | | Grants receivables | 853 | 567 | | Other | 16 | 436 | | Total Other Current Assets | 2,632 | 2,587 | NOTE 5 – OTHER ACCOUNTS PAYABLE Other accounts payable increased to $2,956 thousand as of March 31, 2023, from $2,150 thousand at December 31, 2022, primarily driven by an increase in accrued expenses | Other Accounts Payable (USD in thousands) | March 31, 2023 | December 31, 2022 | | :-------------------------------------- | :------------- | :---------------- | | Employees and related institutions | 789 | 800 | | Accrued expenses | 1,803 | 887 | | Government institutions | 156 | 166 | | Deferred income | 114 | 242 | | Other | 94 | 55 | | Total Other Accounts Payable | 2,956 | 2,150 | NOTE 6 – COMMITMENTS AND CONTINGENCIES BiomX has received significant grants from the Israel Innovation Authority (IIA) for its cystic fibrosis and IBD/PSC programs, totaling approximately $6,960 thousand received through March 31, 2023. Most of these grants are subject to 3-3.5% royalties on future sales, contingent on successful R&D and sales generation. The company also has a research collaboration agreement with Boehringer Ingelheim for IBD, eligible for $1,411 thousand in fees, with $500 thousand received by March 31, 2023 - Through March 31, 2023, BiomX received an aggregate of $6,960 thousand in grants from the IIA for various R&D programs, primarily for cystic fibrosis[70] - IIA grants, excluding the August 2021 program, are subject to 3% to 3.5% royalties on future sales, contingent on successful R&D and sales generation. As of March 31, 2023, the contingent obligation to the IIA was approximately $6,640 thousand[69][70] - A research collaboration agreement with Boehringer Ingelheim for IBD provides for eligible fees totaling $1,411 thousand, with $500 thousand received by March 31, 2023[71] NOTE 7 – LONG-TERM DEBT BiomX has a Loan and Security Agreement with Hercules Capital, Inc. for a $30,000 thousand term loan facility, of which $15,000 thousand was advanced. Subsequent tranches were not reached. The loan accrues interest at a rate based on the Prime Rate plus 5.70% (or 8.95% minimum), with an effective interest rate of 16.79% as of March 31, 2023. Repayments of principal and interest began March 1, 2023, through September 1, 2025. The loan is secured by intellectual property and includes a liquidity covenant requiring a minimum cash balance of $5,000 thousand - BiomX has a $15,000 thousand term loan outstanding from Hercules Capital, Inc., with additional tranches of $10,000 thousand and $5,000 thousand not reached or expected to be reached[73] - The interest rate is the greater of Prime Rate + 5.70% or 8.95%, resulting in an effective interest rate of 16.79% as of March 31, 2023[75] Future Principal Payments (USD in thousands) | Future Principal Payments (USD in thousands) | March 31, 2023 | | :----------------------------------------- | :------------- | | 2023 | $3,842 | | 2024 | $5,785 | | 2025 | $4,954 | | Total principal payments | $14,581 | | Unamortized discount and debt issuance costs | ($59) | | Total future principal payments | $14,522 | | Current portion of long-term debt | ($5,216) | | Long-term debt, net | $9,306 | - The loan is secured by substantially all of the company's intellectual property and includes a liquidity covenant requiring a minimum aggregate compensating cash balance of $5,000 thousand[78] NOTE 8 – STOCKHOLDERS EQUITY Stockholders' equity details include share capital from a Private Investment in Public Equity (PIPE) financing, an At-the-market Sales Agreement, and agreements with Maruho and the Cystic Fibrosis Foundation. The PIPE's first closing in February 2023 generated $1,293 thousand net proceeds. The company also has various outstanding warrants and stock options. Stock-based compensation expenses for Q1 2023 were $175 thousand - The first closing of a Private Investment in Public Equity (PIPE) financing on February 27, 2023, resulted in the issuance of 3,199,491 shares of Common Stock and 2,776,428 pre-funded warrants, generating net proceeds of $1,293 thousand[82] Warrant Details | Warrant Type | Issuance Date | Expiration Date | Exercise Price Per Share | Number of Shares Underlying Warrants | | :--------------------------- | :------------------ | :---------------- | :----------------------- | :----------------------------------- | | Private Placement Warrants | Dec 13, 2018 | Dec 13, 2023 | $11.50 | 2,900,000 | | Public Warrants | Dec 13, 2018 | Oct 28, 2024 | $11.50 | 3,500,000 | | 2021 Registered Direct Offering Warrants | July 28, 2021 | Jan 28, 2027 | $5.00 | 2,812,501 | | Pre-Funded Warrants | Feb 27, 2023 | No expiration date | $0.001 | 2,776,428 | | Total Outstanding Warrants | | | | 11,988,929 | Stock-based Compensation Expenses (USD in thousands) | Stock-based Compensation Expenses (USD in thousands) | Three Months Ended March 31, 2023 | Three Months Ended March 31, 2022 | | :--------------------------------------------------- | :-------------------------------- | :-------------------------------- | | Research and development expenses, net | 87 | 258 | | General and administrative | 88 | 357 | | Total | 175 | 615 | NOTE 9 – BASIC AND DILUTED LOSS PER SHARE Basic loss per share is calculated based on net loss and weighted average common shares outstanding. Diluted loss per share includes potential common shares when dilutive; however, for the three months ended March 31, 2023, 6,114,600 options, 9,215,475 warrants, and 4,000,000 contingent shares were anti-dilutive and thus excluded. Fully vested Pre-Funded Warrants were included - Basic and diluted loss per share for Q1 2023 was $0.20, based on a net loss of $6,361 thousand and 32,125,227 weighted average shares outstanding[25] - Outstanding stock options, warrants, and contingent shares were excluded from diluted EPS calculation for Q1 2023 because their effect would be anti-dilutive[95] NOTE 10 – SUBSEQUENT EVENTS Subsequent to March 31, 2023, BiomX received $700 thousand from Boehringer Ingelheim, final IIA payments of $275 thousand for March 2021 programs, and first IIA payments of $328 thousand for March 2023 programs. The second closing of the PIPE financing was completed on May 4, 2023, following stockholder approval, issuing 24,632,243 securities for approximately $6,000 thousand in gross proceeds - On April 11, 2023, the company received $700 thousand from Boehringer Ingelheim as part of the research collaboration agreement[96] - On April 18, 2023, the company received final payments of approximately $275 thousand from the IIA for March 2021 programs and first payments of approximately $328 thousand for March 2023 programs[96] - The second closing of the PIPE financing occurred on May 4, 2023, after stockholder approval, resulting in the issuance of 24,632,243 securities for approximately $6,000 thousand in gross proceeds[97] Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations This section provides management's perspective on BiomX Inc.'s financial condition and results of operations for the three months ended March 31, 2023. It covers the company's business overview, clinical and pre-clinical development progress, a detailed comparison of financial results, liquidity and capital resources, cash flow analysis, and future outlook. The discussion highlights the corporate restructuring, prioritization of the CF program, and the need for future financing General BiomX is a clinical-stage company utilizing natural and engineered phage technologies to target harmful bacteria in chronic diseases, with a primary focus on cystic fibrosis. Its proprietary BOLT platform enables agile development of phage-based therapies. A corporate restructuring in May 2022 prioritized the CF program and delayed the atopic dermatitis program, involving a 42% reduction in workforce to extend capital resources - BiomX is a clinical-stage company developing phage technologies to target specific harmful bacteria associated with chronic diseases, such as cystic fibrosis (CF)[100] - The company utilizes its proprietary BacteriOphage Lead to Treatment (BOLT) platform for the agile and efficient development of natural or engineered phage combinations[101] - A corporate restructuring in May 2022 prioritized the CF program, delayed the atopic dermatitis (AD) program, and included a layoff of approximately 42% of employees to extend capital resources[103] Clinical and Pre-Clinical Developments BiomX reported positive Part 1 results from its Phase 1b/2a trial for BX004 in cystic fibrosis, showing no safety events, a significant reduction in P. aeruginosa, and no emerging resistance. Part 2 results are expected in Q3 2023. For atopic dermatitis, BX005 received FDA IND approval, with preclinical activities ongoing. Programs for Inflammatory Bowel Disease/Primary Sclerosing Cholangitis (BX003) and Colorectal Cancer are currently on hold due to resource prioritization. COVID-19 has not materially impacted operations to date, but future uncertainty remains Cystic Fibrosis (BX004) BiomX's BX004 for cystic fibrosis showed positive Part 1 Phase 1b/2a trial results, with no safety events and significant P. aeruginosa reduction; Part 2 results are anticipated in Q3 2023 - BX004, a therapeutic phage product candidate for chronic pulmonary infections caused by Pseudomonas aeruginosa in CF patients, showed positive Part 1 results in its Phase 1b/2a trial[104][106] - Part 1 results indicated no safety events, a mean P. aeruginosa CFU reduction of -1.42 log (vs. -0.28 log for placebo), phage detection up to Day 15, and no emerging resistance[106] - Results from Part 2 of the Phase 1b/2a trial, evaluating safety and efficacy in 24 CF patients, are expected in the third quarter of 2023[107] Atopic Dermatitis (BX005) BX005, a topical phage candidate for atopic dermatitis, demonstrated over 90% S. aureus eradication in preclinical studies, with FDA IND approval received and clinical trial timelines under evaluation - BX005 is a topical phage product candidate targeting Staphylococcus aureus, associated with atopic dermatitis, and was shown to eradicate over 90% of S. aureus strains in preclinical studies[109] - The FDA approved the investigational new drug application for BX005 on April 8, 2022, and preclinical activities are ongoing to evaluate timelines for a clinical trial[110][111] Programs on hold Development efforts for BX003 (IBD/PSC) and the Colorectal Cancer program were paused in November 2021 to reallocate resources towards cystic fibrosis and atopic dermatitis programs - Development efforts for BX003 (Inflammatory Bowel Disease and Primary Sclerosing Cholangitis) and the Colorectal Cancer program were paused on November 15, 2021, to prioritize resources for CF and AD programs[113][114] COVID-19 Impact As of May 11, 2023, COVID-19 has not materially impacted operations, but its potential future effects on R&D and financial condition remain uncertain - As of May 11, 2023, COVID-19 has not had a material impact on the company's results of operations, but uncertainty remains regarding its potential future impact on R&D activities and financial condition[114] Consolidated Results of Operations For the three months ended March 31, 2023, BiomX reported a reduced net loss of $6.4 million, down from $8.2 million in the prior year. This improvement was driven by a 6% decrease in R&D expenses (to $4.6 million) and a 36% decrease in General and Administrative expenses (to $1.6 million), primarily due to workforce reduction and delayed AD program activities. Finance income significantly increased by 276% due to rising interest rates and USD appreciation | Metric (USD in thousands) | Three Months Ended March 31, 2023 | Three Months Ended March 31, 2022 | Change | % Change | | :------------------------ | :-------------------------------- | :-------------------------------- | :----- | :------- | | R&D expenses, net | 4,564 | 4,929 | (365) | -7.40% | | General and administrative expenses | 1,644 | 2,477 | (833) | -33.63% | | Operating loss | 6,208 | 7,786 | (1,578) | -20.27% | | Interest expenses | 565 | 461 | 104 | 22.56% | | Finance income, net | (327) | (87) | (240) | 275.86% | | Net loss | 6,361 | 8,169 | (1,808) | -22.13% | | Basic and diluted loss per share | 0.20 | 0.27 | (0.07) | -25.93% | - The decrease in R&D expenses was primarily due to reduced salaries, related expenses, and stock-based compensation from workforce reduction and delayed AD program activities, partially offset by CF clinical trial expenses[115] - The increase in finance income, net, was primarily due to rising interest rates leading to higher interest income and the appreciation of the U.S. dollar against the NIS[119] Liquidity and Capital Resources BiomX anticipates its current cash and cash equivalents, along with short-term deposits, will fund operations until Q3 2024. The company has implemented expense reductions, including a corporate restructuring and subleasing office space. Future funding will likely be sought through public or private equity, debt financings, loans, and grants to support ongoing operations and potential expansion of development plans - The company believes its cash and cash equivalents and short-term deposits are sufficient to meet working capital and capital expenditure requirements until into the third quarter of 2024[121] - Operating plans have been revised to reduce expenses, including a corporate restructuring that significantly reduced employee-related costs and subleasing a portion of office space[121] - Future additional funds will likely be raised through public or private equity, debt financings, loans, governmental or other grants, or collaborative agreements[121] Cash Flows In Q1 2023, net cash used in operating activities decreased to $5.0 million from $7.4 million in Q1 2022, primarily due to a lower net loss and changes in operating assets/liabilities. Investing activities provided $2.0 million in cash, a significant shift from $10.0 million used in Q1 2022, mainly from proceeds from short-term deposits. Financing activities provided $1.1 million, largely due to the first closing of the PIPE, compared to $37 thousand in Q1 2022 | Cash Flow Activity (USD in thousands) | Three Months Ended March 31, 2023 | Three Months Ended March 31, 2022 | | :------------------------------------ | :-------------------------------- | :-------------------------------- | | Net cash used in operating activities | (5,045) | (7,363) | | Net cash provided by (used in) investing activities | 1,990 | (10,020) | | Net cash provided by financing activities | 1,050 | 37 | - Net cash used in operating activities decreased by $2.3 million, primarily due to a lower net loss and favorable changes in operating assets and liabilities[123][124] - Net cash provided by investing activities in Q1 2023 was mainly from $2.0 million in proceeds from short-term deposits, contrasting with $10.0 million used for investments in Q1 2022[125] - Net cash provided by financing activities increased significantly due to $1.5 million from the first closing of the PIPE, partially offset by long-term debt repayment[127] Outlook BiomX has an accumulated deficit of $143.2 million and does not expect significant revenue in the next twelve months. With existing liquidity and additional proceeds from the PIPE's second closing, the company projects sufficient funds until Q3 2024. It plans to secure further capital through equity, debt, loans, and grants to support ongoing R&D and potential new product candidates - BiomX has an accumulated deficit of $143.2 million and does not expect to generate significant revenues from product sales in the next twelve months[133] - The company's liquidity resources, including cash, cash equivalents, short-term deposits, restricted cash ($30.3 million as of March 31, 2023), and an additional $6 million from the PIPE's second closing, are expected to fund operations until Q3 2024[133] - Future funding will be sought through public or private equity, debt securities, loans, and additional grants to support ongoing R&D and development of new product candidates[134] Item 3. Quantitative and Qualitative Disclosures About Market Risk As a smaller reporting company, BiomX Inc. is not required to provide disclosures under this item - As a smaller reporting company, BiomX Inc. is exempt from providing disclosures under Item 3[136] Item 4. Controls and Procedures BiomX Inc.'s management, including its principal executive and financial officers, concluded that the company's disclosure controls and procedures were effective as of March 31, 2023. There have been no material changes in internal control over financial reporting during the quarter - Management concluded that the company's disclosure controls and procedures were effective as of March 31, 2023[138] - There were no material changes in internal control over financial reporting during the quarter ended March 31, 2023[139] PART II - OTHER INFORMATION This section lists the exhibits filed with BiomX Inc.'s Form 10-Q, including corporate governance documents and XBRL data files Item 6. Exhibits This section lists the exhibits filed with the Form 10-Q, including the company's Amended and Restated Certificate of Incorporation, Bylaws, Form of Indemnification Agreement, certifications from principal officers, and Inline XBRL documents - Exhibits include the Composite Copy of Amended and Restated Certificate of Incorporation, Amended and Restated Bylaws, Form of Indemnification Agreement, and certifications of principal executive and financial officers[141] - The filing also includes Inline XBRL Instance Document, Taxonomy Extension Schema Document, Calculation Linkbase Document, Definition Linkbase Document, Label Linkbase Document, Presentation Linkbase Document, and Cover Page Interactive Data File[141] PART III - SIGNATURES This section contains the official signatures of BiomX Inc.'s principal executive and financial officers, certifying the accuracy of the Form 10-Q filing Signatures The report is duly signed on behalf of BiomX Inc. by Jonathan Solomon, Chief Executive Officer, and Marina Wolfson, Chief Financial Officer and Principal Accounting Officer, on May 15, 2023 - The report was signed by Jonathan Solomon, Chief Executive Officer, and Marina Wolfson, Chief Financial Officer and Principal Accounting Officer, on May 15, 2023[147]